Evidence map›Paper›PMID 32202298›Full record

ArticleHuman molecular genetics2020

Distinct effects on mRNA export factor GANP underlie neurological disease phenotypes and alter gene expression depending on intron content.

Rosa Woldegebriel, Jouni Kvist, Noora Andersson, Katrin Õunap, Karit Reinson, Monica H Wojcik, Emilia K Bijlsma, Mariëtte J V Hoffer, Monique M Ryan, Zornitza Stark and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Genetic aspects of ataxias in a cohort of Turkish patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  5. Identification of biallelic mutations inFrontiers in genetics · 2024
    Article
  6. Article
  7. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 17 institutions in 6 countries.

Rosa WoldegebrielStem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, 00290 Helsinki, Finland.
Jouni KvistStem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, 00290 Helsinki, Finland.
Noora AnderssonDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Katrin ÕunapDepartment of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
Karit ReinsonDepartment of Clinical Genetics, United Laboratories, Tartu University Hospital, Tartu, Estonia.
Monica H WojcikBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Emilia K BijlsmaDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands.
Mariëtte J V HofferDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, the Netherlands.
Monique M RyanMurdoch Children's Research Institute, Melbourne 3052, Australia.
Zornitza StarkMurdoch Children's Research Institute, Melbourne 3052, Australia.
Maie WalshMurdoch Children's Research Institute, Melbourne 3052, Australia.
Inge CuppenDepartment of Pediatric Neurology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
Marie-Jose H van den BoogaardDepartment of Genetics, University Medical Center Utrecht, The Netherlands.
Diana Bharucha-GoebelNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Sandra DonkervoortNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Sara WinchesterChild Neurology Center of Northwest Florida, Pensacola, FL, USA.
Roberto ZoriDivision of Genetics and Metabolism, University of Florida, Gainesville, FL, USA.
Carsten G BönnemannNeuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Reza MaroofianDepartment of Neuromuscular Disorders, UCL Institute of Neurology, London WC1N 3BG, UK.
Emer O'ConnorDepartment of Neuromuscular Disorders, UCL Institute of Neurology, London WC1N 3BG, UK.
Henry HouldenDepartment of Neuromuscular Disorders, UCL Institute of Neurology, London WC1N 3BG, UK.
Fang ZhaoDepartment of Pathology and Genetics, HUSLAB Laboratories, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
Olli CarpénDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Matthew WhiteMaurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Jemeen SreedharanMaurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Murray StewartMRC Laboratory of Molecular Biology, Francis Crick Ave, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK.
Emil YlikallioStem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, 00290 Helsinki, Finland.
Henna TyynismaaStem Cells and Metabolism Research Program, Research Programs Unit, University of Helsinki, 00290 Helsinki, Finland.
Helsinki University Hospital · FIKing's College London · GBUniversity College London · GBUniversity of Helsinki · FILeiden University · NLMurdoch Children's Research Institute · AUChildren's National · USHarvard University · USMRC Laboratory of Molecular Biology · GBNational Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USRoyal Children's Hospital · AUTartu University Hospital · EEUniversity Medical Center Utrecht · NLUniversity of Florida · USUniversity of Tartu · EEWilhelmina Children's Hospital · NL

Funding

Molecular and Clinical Manifestations of Matrix and Aggregate MyopathiesZIANS003129 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI BÖNNEMANN, CARSTEN · 2011 to 2025
$52.8M
Joint Center for Mendelian GenomicsUM1HG008900 · NHGRI · BROAD INSTITUTE, INC. · PI O'DONNELL-LURIA, ANNE, REHM, HEIDI L · 2016 to 2020
$16.5M
TRAINING GRANT IN GENETICST32GM007748 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Anne O'Donnell-Luria, Louise Wilkins-Haug · 1985 to 2026
$12.0M
Medical Research Council MC_U105178939Medical Research Council MC_UP_1201/6Medical Research Council MR/K010611/1NHGRI NIH HHS UM1 HG008900NIGMS NIH HHS T32 GM007748
6 · The paper itself

Abstract

Defects in the mRNA export scaffold protein GANP, encoded by the MCM3AP gene, cause autosomal recessive early-onset peripheral neuropathy with or without intellectual disability. We extend here the phenotypic range associated with MCM3AP variants, by describing a severely hypotonic child and a sibling pair with a progressive encephalopathic syndrome. In addition, our analysis of skin fibroblasts from affected individuals from seven unrelated families indicates that disease variants result in depletion of GANP except when they alter critical residues in the Sac3 mRNA binding domain. GANP depletion was associated with more severe phenotypes compared with the Sac3 variants. Patient fibroblasts showed transcriptome alterations that suggested intron content-dependent regulation of gene expression. For example, all differentially expressed intronless genes were downregulated, including ATXN7L3B, which couples mRNA export to transcription activation by association with the TREX-2 and SAGA complexes. Our results provide insight into the molecular basis behind genotype-phenotype correlations in MCM3AP-associated disease and suggest mechanisms by which GANP defects might alter RNA metabolism.

Indexed as

AcetyltransferasesAge of OnsetAntigens, SurfaceCell NucleusChildChild, PreschoolExodeoxyribonucleasesFemaleFlavoproteinsGene Expression RegulationGlycoproteinsHumansIntellectual DisabilityIntracellular Signaling Peptides and ProteinsIntronsMaleAcetyltransferasesAntigens, SurfaceATXN7L3B protein, humanExodeoxyribonucleasesFIG4 protein, humanFlavoproteinsGlycoproteinsIntracellular Signaling Peptides and ProteinsMCM3AP protein, humanNuclear ProteinsPCID2 protein, humanPhosphoproteinsPhosphoric Monoester HydrolasesRNA, MessengerSAGA-1 protein, humanTranscription FactorsTREX2 protein, human

Identifiers

PMID32202298
PMCPMC7297229
OpenAlexW3012865422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.